UCB’s Next Allergy Partner Is Sanofi-Aventis
This article was originally published in The Pink Sheet Daily
Executive Summary
Xyzal, pending in the U.S. for allergic rhinitis treatment, could be a replacement for Allegra.
You may also be interested in...
UCB/Sanofi’s Xyzal Clears FDA As Once-Daily Antihistamine
Xyzal will be available for the fall allergy season after being approved for symptoms associated with seasonal and perennial allergic rhinitis.
UCB/Sanofi’s Xyzal Clears FDA As Once-Daily Antihistamine
Xyzal will be available for the fall allergy season after being approved for symptoms associated with seasonal and perennial allergic rhinitis.
UCB Receives “Complete Response” Letter For Cimzia
Firm says FDA seeks new information and clarification regarding the BLA.